HRGN Company Description
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects.
The company’s pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair.
Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease.
The company also sells Longevity products that focuses on personal healthcare, including longevity dietary supplements.
Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023.
The company was founded in 2009 and is headquartered in Holliston, Massachusetts.
| Country | United States |
| Founded | 2009 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 18 |
| CEO | Junli He |
Contact Details
Address: 84 October Hill Road Holliston, Delaware 01746 United States | |
| Phone | 774 233 7300 |
| Website | hregen.com |
Stock Details
| Ticker Symbol | HRGN |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Junli He C.F.A. | Chief Executive Officer and Chairman |
| Yu Hong | President |
| Joseph L. Damasio Jr. | Chief Financial Officer |
| Dr. William L. Fodor Ph.D. | Chief Scientific Officer |
| Dr. Shunfu Hu Ph.D. | Vice President of Business Development and Operations |